169 related articles for article (PubMed ID: 26576691)
1. Endo180 at the cutting edge of bone cancer treatment and beyond.
Sturge J
J Pathol; 2016 Mar; 238(4):485-8. PubMed ID: 26576691
[TBL] [Abstract][Full Text] [Related]
2. Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180.
Engelholm LH; Melander MC; Hald A; Persson M; Madsen DH; Jürgensen HJ; Johansson K; Nielsen C; Nørregaard KS; Ingvarsen SZ; Kjaer A; Trovik CS; Laerum OD; Bugge TH; Eide J; Behrendt N
J Pathol; 2016 Jan; 238(1):120-33. PubMed ID: 26466547
[TBL] [Abstract][Full Text] [Related]
3. TGFβ1-Endo180-dependent collagen deposition is dysregulated at the tumour-stromal interface in bone metastasis.
Caley MP; Kogianni G; Adamarek A; Gronau JH; Rodriguez-Teja M; Fonseca AV; Mauri F; Sandison A; Rhim JS; Pchejetski D; Palmieri C; Cobb JP; Waxman J; Sturge J
J Pathol; 2012 Apr; 226(5):775-83. PubMed ID: 22072289
[TBL] [Abstract][Full Text] [Related]
4. AGE-modified basement membrane cooperates with Endo180 to promote epithelial cell invasiveness and decrease prostate cancer survival.
Rodriguez-Teja M; Gronau JH; Breit C; Zhang YZ; Minamidate A; Caley MP; McCarthy A; Cox TR; Erler JT; Gaughan L; Darby S; Robson C; Mauri F; Waxman J; Sturge J
J Pathol; 2015 Mar; 235(4):581-92. PubMed ID: 25408555
[TBL] [Abstract][Full Text] [Related]
5. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.
Ohba T; Cole HA; Cates JM; Slosky DA; Haro H; Ando T; Schwartz HS; Schoenecker JG
J Bone Miner Res; 2014 Jun; 29(6):1431-45. PubMed ID: 24443409
[TBL] [Abstract][Full Text] [Related]
7. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
8. Examination of the mechanisms of osteolysis in patients with metastatic breast cancer.
Trinkaus M; Ooi WS; Amir E; Popovic S; Kalina M; Kahn H; Singh G; Gainford MC; Clemons M
Oncol Rep; 2009 May; 21(5):1153-9. PubMed ID: 19360288
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Osteoblast Migration Involving Receptor Activator of Nuclear Factor-kappa B (RANK) Signaling.
Golden D; Saria EA; Hansen MF
J Cell Physiol; 2015 Dec; 230(12):2951-60. PubMed ID: 25893522
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms underlying the inhibitory effects of bovine lactoferrin on osteosarcoma.
Chea C; Haing S; Miyauchi M; Shrestha M; Imanaka H; Takata T
Biochem Biophys Res Commun; 2019 Jan; 508(3):946-952. PubMed ID: 30545626
[TBL] [Abstract][Full Text] [Related]
11. Does collagen trigger the recruitment of osteoblasts into vacated bone resorption lacunae during bone remodeling?
Abdelgawad ME; Søe K; Andersen TL; Merrild DM; Christiansen P; Kjærsgaard-Andersen P; Delaisse JM
Bone; 2014 Oct; 67():181-8. PubMed ID: 25019594
[TBL] [Abstract][Full Text] [Related]
12. The collagen receptor uPARAP/Endo180.
Engelholm LH; Ingvarsen S; Jürgensen HJ; Hillig T; Madsen DH; Nielsen BS; Behrendt N
Front Biosci (Landmark Ed); 2009 Jan; 14(6):2103-14. PubMed ID: 19273187
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2.
Nadiminty N; Lou W; Lee SO; Mehraein-Ghomi F; Kirk JS; Conroy JM; Zhang H; Gao AC
Clin Cancer Res; 2006 Mar; 12(5):1420-30. PubMed ID: 16533764
[TBL] [Abstract][Full Text] [Related]
14. Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts.
Akiyama T; Dass CR; Shinoda Y; Kawano H; Tanaka S; Choong PF
J Pharm Pharmacol; 2010 Apr; 62(4):470-6. PubMed ID: 20604836
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer metastasis to the bone: mechanisms of bone loss.
Chen YC; Sosnoski DM; Mastro AM
Breast Cancer Res; 2010; 12(6):215. PubMed ID: 21176175
[TBL] [Abstract][Full Text] [Related]
16. [Mechanism for bone metastasis].
Futakuchi M; Sato S
Clin Calcium; 2014 Aug; 24(8):1137-43. PubMed ID: 25065864
[TBL] [Abstract][Full Text] [Related]
17. Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer.
Palmieri C; Caley MP; Purshouse K; Fonseca AV; Rodriguez-Teja M; Kogianni G; Woodley L; Odendaal J; Elliott K; Waxman J; Sturge J
Br J Cancer; 2013 Jan; 108(1):163-9. PubMed ID: 23257899
[TBL] [Abstract][Full Text] [Related]
18. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
19. The collagen receptor uPARAP/Endo180 in tissue degradation and cancer (Review).
Melander MC; Jürgensen HJ; Madsen DH; Engelholm LH; Behrendt N
Int J Oncol; 2015 Oct; 47(4):1177-88. PubMed ID: 26316068
[TBL] [Abstract][Full Text] [Related]
20. Expression of receptor activator of nuclear factor kappa-B ligand (RANKL) in neoplasms of dogs and cats.
Barger AM; Fan TM; de Lorimier LP; Sprandel IT; O'Dell-Anderson K
J Vet Intern Med; 2007; 21(1):133-40. PubMed ID: 17338161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
